查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1803084

2032 年肝纤维化治疗市场预测：按治疗类型、疾病状况、通路和地区进行的全球分析

Liver Fibrosis Treatment Market Forecasts to 2032 - Global Analysis By Treatment Type, Condition, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球肝纤维化治疗市场预计在 2025 年达到 207.1 亿美元，预计到 2032 年将达到 488.7 亿美元，预测期内的复合年增长率为 13.05%。

肝纤维化的治疗旨在减少或逆转持续性肝损伤和发炎引起的疤痕组织形成。治疗包括控制潜在原因，例如病毒性肝炎、饮酒或非酒精性脂肪性肝病，并透过药物治疗、生活方式改变和支持性治疗相结合的方式，最大限度地减少进一步的损害。及时治疗可保护肝功能，减缓病情进展，降低肝硬化的风险，最终改善整体健康状况和预后。

根据美国国家酒精滥用和酒精成瘾研究所 (2023) 的数据，到 2022 年，美国将有约 2,950 万人遭受酒精成瘾困扰，占 12 岁及以上人口的 10.5%。

老年人口不断增加

全球人口老化显着推动了肝纤维化治疗的需求。由于老龄化相关的免疫力减弱以及长期暴露于代谢压力源，老年人更容易受到肝损伤。肥胖、糖尿病和心臟病等疾病通常并存，并加速肝臟功能恶化。随着人们寿命的延长，医疗保健提供者发现老年患者需要客製化治疗方法。这一趋势正在推动医药创新，专注于为老年人提供更安全、更有效的抗纤维化药物选择。最终，人口老化正在扩大治疗市场，并影响临床开发的方向。

核准的抗纤维化药物供应有限

大多数现有疗法着重于控制潜在病因，例如病毒性肝炎和脂肪肝，而非逆转纤维化疾病。复杂的监管和漫长的研发週期阻碍了新治疗方法的推广。许多有前景的化合物仍处于早期研究阶段，导致临床医生难以找到合适的治疗方案。这种药物短缺影响了患者护理，并限制了市场扩张，尤其是在高负担地区。在更多抗纤维化药物核准之前，治疗方案可能仍然有限。

远端医疗和数位健康平台的扩展

数位医疗和远端医疗的兴起为肝纤维化的管理开闢了新的途径。虚拟会诊使患者能够联繫肝病专家并获得及时治疗，尤其是在偏远和服务不足的地区。穿戴式装置和行动应用程式可以监测肝功能指标并支持药物依从性。这些技术还能实现个人化治疗方案，改善病患教育，并促进更好的健康结果。随着数位医疗成为主流，肝纤维化的治疗正变得更加积极且易于获得。预计这一转变将促进创新治疗方法的广泛应用，并加强疾病管理。

来自替代疗法的竞争

替代疗法正日益挑战传统肝纤维化治疗的优势。生活型态改变、饮食介入和代谢控制等预防策略正逐渐成为第一线治疗手段。再生技术和细胞疗法也提供了绕过传统药物治疗的全新解决方案。这些日益广泛的治疗选择或许可以减少对药物介入的依赖。此外，如果非侵入性方法被证明有效，临床医生在采用新药时可能会更加谨慎。

COVID-19的影响：

COVID-19疫情对肝纤维化治疗市场造成了显着影响，导致诊断、常规检查和不必要的医疗程序延误。治疗计划经常被推迟，这可能导致部分患者的病情恶化。供应链中断阻碍了药品和诊断工具的供应。 COVID-19对肝功能的潜在影响凸显了早期发现和有效治疗的重要性。

过氧化物酶体增殖剂部分预计将在预测期内成为最大的

由于高通量筛检和分子建模等药物发现技术的进步，过氧化物酶体增殖物领域预计将在预测期内占据最大的市场占有率。诸如双PPAR促效剂和泛PPAR促效剂的开发等新兴趋势提供了更广泛的治疗益处。关键进展包括令人鼓舞的临床试验结果以及製药公司之间为加速创新而建立的策略联盟。非酒精性脂肪性肝炎(NASH)及其相关代谢紊乱的盛行率不断上升，使得基于PPAR的疗法成为肝纤维化管理的关键领域，从而进一步推动需求。

预计医院药房部门在预测期内将出现最高的复合年增长率。

随着自动配药和电子处方系统等配药技术的进步，医院药局预计将在预测期内实现最高成长率。新兴趋势包括整合远距配药服务以及针对肝病患者的个人化医疗方案。此外，医院与製药公司合作进行临床试验以及加速药物可及性计画等发展也取得了进展。肝臟相关疾病住院率的上升以及先进治疗方法的日益普及，进一步加强了医院药房在医疗服务中的作用。

占比最大的地区：

由于与肝炎、非酒精性脂肪性肝炎 (NASH) 和酒精性肝损伤相关的病例增加，预计亚太地区将在预测期内占据最大的市场占有率。非侵入性成像和 RNA 疗法的技术创新正在增强早期诊断和标靶治疗。市场对数位健康和​​个人化治疗方法的采用正在增长。值得注意的发展包括印度、日本和中国候选药物和测试活动的扩展。人口老化、健康意识的增强以及政府投资的增加正在推动技术进步和区域市场的成长。

复合年增长率最高的地区：

在预测期内，北美预计将见证最高的复合年增长率，这得益于北美强大的医疗体系和研究资金的支持，以及NASH、NAFLD和肝炎的盛行率不断上升。人工智慧主导的诊断、非侵入性技术和RNA疗法的突破正在提高准确性和早期疗育。远端医疗和个人化治疗等趋势也在推动市场发展。最近的发展包括新的PPAR标靶药物、联合治疗和不断扩大的临床试验网络。不断提高的健康素养、有利的法规和活跃的药物研发线正在推动全部区域市场的持续扩张。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球肝纤维化治疗市场（依治疗类型）

  • 血管紧张素转换酶抑制剂
  • 抗病毒药物
  • 细胞疗法
  • 过氧化物酶体增殖物
  • FXR促效剂
  • 标靶治疗
  • 肝病药物
  • 其他治疗类型

6. 全球肝纤维化治疗市场（依疾病类型）

  • 非酒精性脂肪性肝炎（NASH）
  • 慢性肝病
  • C型肝炎
  • 酒精性肝臟疾病
  • 遗传性疾病
  • 自体免疫肝炎

7. 全球肝纤维化治疗市场（按分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

8. 全球肝纤维化治疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第九章：主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章：企业概况

  • Abbott Laboratories
  • Bristol-Myers Squibb Company
  • Akero Therapeutics
  • Hepion Pharmaceuticals
  • Alentis Therapeutics
  • Inventiva Pharma
  • Alnylam Pharmaceuticals
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Novartis AG
  • Boehringer Ingelheim
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi AG
  • Vertex Pharmaceuticals Incorporated
  • Galectin Therapeutics, Inc.
  • Takeda Pharmaceutical Company
  • Gilead Sciences, Inc.
  • Madrigal Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
Product Code: SMRC30609

According to Stratistics MRC, the Global Liver Fibrosis Treatment Market is accounted for $20.71 billion in 2025 and is expected to reach $48.87 billion by 2032 growing at a CAGR of 13.05% during the forecast period. Treatment for liver fibrosis targets the reduction or reversal of scar tissue formation resulting from ongoing liver damage or inflammation. It involves managing the root cause like viral hepatitis, alcohol consumption, or nonalcoholic fatty liver alongside medications, lifestyle modifications, and supportive care to minimize further harm. Timely treatment helps preserve liver function, slows disease progression, and lowers the risk of developing cirrhosis, ultimately improving overall health and prognosis.

According to the National Institute on Alcohol Abuse and Alcoholism 2023, in 2022, about 29.5 million individuals in the United States with alcohol dependence, or 10.5% of individuals aged between 12 years and above.

Market Dynamics:

Driver:

Growing geriatric population

The increasing number of elderly individuals worldwide is significantly boosting demand for liver fibrosis treatments. Older adults are more prone to liver disorders due to age-related immune decline and long-term exposure to metabolic stressors. Conditions like obesity, diabetes, and heart disease often coexist, accelerating liver deterioration. As longevity rises, healthcare providers are seeing a growing need for therapies tailored to older patients. This trend is encouraging pharmaceutical innovation focused on safer and more effective anti-fibrotic options for seniors. Eventually, the aging demographic is expanding the treatment market and influencing the direction of clinical development.

Restraint:

Limited availability of approved anti-fibrotic drugs

Most available therapies concentrate on managing underlying causes such as viral hepatitis or fatty liver disease, rather than reversing fibrotic damage. Regulatory complexities and extended development timelines have slowed the introduction of new treatments. Many promising compounds are still in early research phases, leaving clinicians with few targeted solutions. This shortage affects patient care and restricts market expansion, particularly in high-burden regions. Until more anti-fibrotic agents receive approval, treatment options will remain constrained.

Opportunity:

Expansion of telemedicine and digital health platforms

The rise of digital health and telemedicine is opening new avenues for managing liver fibrosis. Virtual consultations allow patients to access liver specialists and receive timely care, especially in remote or underserved areas. Wearables and mobile apps can monitor liver function indicators and support medication adherence. These technologies also enable customized treatment plans and improve patient education, fostering better health outcomes. As digital healthcare becomes mainstream, liver fibrosis care is becoming more proactive and accessible. This shift is expected to drive broader adoption of innovative therapies and enhance disease management.

Threat:

Competition from alternative therapies

Alternative therapies are increasingly challenging the dominance of traditional liver fibrosis treatments. Preventive strategies like lifestyle changes, dietary interventions, and metabolic control are gaining traction as first-line approaches. Regenerative techniques and cell-based therapies also offer novel solutions that may bypass conventional drug treatments. This expanding range of options could reduce reliance on pharmacological interventions. Additionally, clinicians may be cautious about adopting new drugs if non-invasive methods prove effective.

Covid-19 Impact:

The COVID-19 pandemic had a notable effect on the Liver Fibrosis Treatment Market, causing delays in diagnostics, routine check-ups, and non-essential medical procedures. Treatment schedules were often postponed, resulting in possible disease advancement for some patients. Disruptions in supply chains hindered the availability of medicines and diagnostic tools. On the positive side, the crisis spurred the adoption of telemedicine and heightened awareness of liver health, as COVID-19's potential impact on liver function emphasized the importance of early detection and effective care.

The peroxisome proliferator segment is expected to be the largest during the forecast period

The peroxisome proliferator segment is expected to account for the largest market share during the forecast period, driven by advancements in drug discovery technologies, including high-throughput screening and molecular modelling. Emerging trends such as the development of dual and pan-PPAR agonists offer broader therapeutic benefits. Key developments include promising clinical trial results and strategic collaborations between pharmaceutical companies to accelerate innovation. Increasing prevalence of nonalcoholic steatohepatitis (NASH) and related metabolic disorders further fuels demand, positioning PPAR-based treatments as a vital segment in liver fibrosis management.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospital pharmacies segment is predicted to witness the highest growth rate, driven by advancements in pharmaceutical dispensing technologies, such as automated drug distribution and electronic prescription systems, enhancing efficiency and accuracy. Emerging trends include integration of telepharmacy services and personalized medicine approaches for liver disease patients. Developments like hospital collaborations with pharmaceutical companies for clinical trials and early drug access programs. Rising hospitalization rates for liver-related conditions and increasing availability of advanced therapies further strengthen the role of hospital pharmacies in treatment delivery.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to escalating cases linked to hepatitis, NASH, and alcohol-induced liver damage. Innovations in non-invasive imaging and RNA therapeutics are enhancing early diagnosis and targeted care. The market is seeing growth in digital health adoption and personalized treatment approaches. Notable progress includes new drug candidates and expanded trial activity in India, Japan, and China. Aging populations, rising health awareness, and increased government investment are fueling technological advancement and regional market growth.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, due to growing prevalence of NASH, NAFLD, and hepatitis, supported by robust healthcare systems and research funding. Breakthroughs in AI-driven diagnostics, non-invasive technologies, and RNA therapeutics are improving accuracy and early intervention. Trends like telemedicine and tailored treatment approaches are gaining traction. Recent progress includes new PPAR-targeting drugs, multi-modal regimens, and expanded trial networks. Rising health literacy, favourable regulations, and active pharmaceutical pipelines are driving sustained market expansion across the region.

Key players in the market

Some of the key players in Liver Fibrosis Treatment Market include Abbott Laboratories, Bristol-Myers Squibb Company, Akero Therapeutics, Hepion Pharmaceuticals, Alentis Therapeutics, Inventiva Pharma, Alnylam Pharmaceuticals, Johnson & Johnson, Astellas Pharma Inc., Novartis AG, Boehringer Ingelheim, Merck & Co., Inc., Pfizer Inc., Sanofi AG, Vertex Pharmaceuticals Incorporated, Galectin Therapeutics, Inc., Takeda Pharmaceutical Company, Gilead Sciences, Inc., Madrigal Pharmaceuticals, Inc., and GlaxoSmithKline PLC.

Key Developments:

In July 2025, Johnson & Johnson MedTech announced a strategic co-promotion agreement with Pacira BioSciences, Inc., the industry leader in the delivery of innovative, non-opioid pain therapies. The agreement expands the Company's Early Intervention portfolio with ZILRETTA(R) (triamcinolone acetonide extended-release injectable suspension) an extended-release injectable for treatment of pain related to osteoarthritis (OA) of the knee.

In June 2025, Bristol Myers Squibb and BioNTech SE announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.

In February 2025, Abbott and Shedd Aquarium are announcing one of Shedd's largest corporate gifts in recent history - a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.

Treatment Types Covered:

  • ACE Inhibitors
  • Antiviral Drugs
  • Cell Therapy
  • Peroxisome Proliferator
  • FXR Agonists
  • Targeted Therapy
  • Hepatotropic Drugs
  • Other Treatment Types

Conditions Covered:

  • Nonalcoholic Steatohepatitis (NASH)
  • Chronic Liver Diseases
  • Hepatitis C
  • Alcoholic Liver Disease
  • Genetic Disorders
  • Autoimmune Hepatitis

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Liver Fibrosis Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 ACE Inhibitors
  • 5.3 Antiviral Drugs
  • 5.4 Cell Therapy
  • 5.5 Peroxisome Proliferator
  • 5.6 FXR Agonists
  • 5.7 Targeted Therapy
  • 5.8 Hepatotropic Drugs
  • 5.9 Other Treatment Types

6 Global Liver Fibrosis Treatment Market, By Condition

  • 6.1 Introduction
  • 6.2 Nonalcoholic Steatohepatitis (NASH)
  • 6.3 Chronic Liver Diseases
  • 6.4 Hepatitis C
  • 6.5 Alcoholic Liver Disease
  • 6.6 Genetic Disorders
  • 6.7 Autoimmune Hepatitis

7 Global Liver Fibrosis Treatment Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Online Pharmacies
  • 7.4 Retail Pharmacies

8 Global Liver Fibrosis Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott Laboratories
  • 10.2 Bristol-Myers Squibb Company
  • 10.3 Akero Therapeutics
  • 10.4 Hepion Pharmaceuticals
  • 10.5 Alentis Therapeutics
  • 10.6 Inventiva Pharma
  • 10.7 Alnylam Pharmaceuticals
  • 10.8 Johnson & Johnson
  • 10.9 Astellas Pharma Inc.
  • 10.10 Novartis AG
  • 10.11 Boehringer Ingelheim
  • 10.12 Merck & Co., Inc.
  • 10.13 Pfizer Inc.
  • 10.14 Sanofi AG
  • 10.15 Vertex Pharmaceuticals Incorporated
  • 10.16 Galectin Therapeutics, Inc.
  • 10.17 Takeda Pharmaceutical Company
  • 10.18 Gilead Sciences, Inc.
  • 10.19 Madrigal Pharmaceuticals, Inc.
  • 10.20 GlaxoSmithKline PLC

List of Tables

  • Table 1 Global Liver Fibrosis Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 3 Global Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
  • Table 4 Global Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
  • Table 5 Global Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 6 Global Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
  • Table 7 Global Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
  • Table 8 Global Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 9 Global Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
  • Table 10 Global Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 11 Global Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
  • Table 12 Global Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
  • Table 13 Global Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
  • Table 14 Global Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 15 Global Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
  • Table 16 Global Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 17 Global Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
  • Table 18 Global Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 19 Global Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 20 Global Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 21 Global Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 22 North America Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 23 North America Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 24 North America Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
  • Table 25 North America Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
  • Table 26 North America Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 27 North America Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
  • Table 28 North America Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
  • Table 29 North America Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 30 North America Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
  • Table 31 North America Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 32 North America Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
  • Table 33 North America Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
  • Table 34 North America Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
  • Table 35 North America Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 36 North America Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
  • Table 37 North America Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 38 North America Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
  • Table 39 North America Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 40 North America Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 41 North America Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 42 North America Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 43 Europe Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 44 Europe Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 45 Europe Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
  • Table 46 Europe Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
  • Table 47 Europe Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 48 Europe Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
  • Table 49 Europe Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
  • Table 50 Europe Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 51 Europe Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
  • Table 52 Europe Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 53 Europe Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
  • Table 54 Europe Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
  • Table 55 Europe Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
  • Table 56 Europe Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 57 Europe Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
  • Table 58 Europe Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 59 Europe Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
  • Table 60 Europe Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 61 Europe Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 62 Europe Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 63 Europe Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 64 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 65 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 66 Asia Pacific Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
  • Table 67 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
  • Table 68 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 69 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
  • Table 70 Asia Pacific Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
  • Table 71 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 72 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
  • Table 73 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 74 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
  • Table 75 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
  • Table 76 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
  • Table 77 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 78 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
  • Table 79 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 80 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
  • Table 81 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 82 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 83 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 84 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 85 South America Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 86 South America Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 87 South America Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
  • Table 88 South America Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
  • Table 89 South America Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 90 South America Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
  • Table 91 South America Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
  • Table 92 South America Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 93 South America Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
  • Table 94 South America Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 95 South America Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
  • Table 96 South America Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
  • Table 97 South America Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
  • Table 98 South America Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 99 South America Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
  • Table 100 South America Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 101 South America Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
  • Table 102 South America Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 103 South America Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 104 South America Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 105 South America Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 106 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 107 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 108 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
  • Table 109 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
  • Table 110 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 111 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
  • Table 112 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
  • Table 113 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 114 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
  • Table 115 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 116 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
  • Table 117 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
  • Table 118 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
  • Table 119 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 120 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
  • Table 121 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 122 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
  • Table 123 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 124 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 125 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 126 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)